73 related articles for article (PubMed ID: 15120619)
1. Novel function of PS2V: change in conformation of tau proteins.
Nishikawa A; Manabe T; Katayama T; Kudo T; Matsuzaki S; Yanagita T; Okuda H; Bando Y; Tohyama M
Biochem Biophys Res Commun; 2004 May; 318(2):435-8. PubMed ID: 15120619
[TBL] [Abstract][Full Text] [Related]
2. Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease.
Woodhouse A; Shepherd CE; Sokolova A; Carroll VL; King AE; Halliday GM; Dickson TC; Vickers JC
Acta Neuropathol; 2009 Jan; 117(1):19-29. PubMed ID: 19015863
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
4. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation.
Sato S; Cerny RL; Buescher JL; Ikezu T
J Neurochem; 2006 Sep; 98(5):1573-84. PubMed ID: 16923168
[TBL] [Abstract][Full Text] [Related]
5. Metals accelerate production of the aberrant splicing isoform of the presenilin-2.
Matsuzaki S; Manabe T; Katayama T; Nishikawa A; Yanagita T; Okuda H; Yasuda Y; Miyata S; Meshitsuka S; Tohyama M
J Neurochem; 2004 Mar; 88(6):1345-51. PubMed ID: 15009634
[TBL] [Abstract][Full Text] [Related]
6. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease.
Alvarez-de-la-Rosa M; Silva I; Nilsen J; Pérez MM; García-Segura LM; Avila J; Naftolin F
Ann N Y Acad Sci; 2005 Jun; 1052():210-24. PubMed ID: 16024764
[TBL] [Abstract][Full Text] [Related]
7. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.
Guillozet-Bongaarts AL; Garcia-Sierra F; Reynolds MR; Horowitz PM; Fu Y; Wang T; Cahill ME; Bigio EH; Berry RW; Binder LI
Neurobiol Aging; 2005 Jul; 26(7):1015-22. PubMed ID: 15748781
[TBL] [Abstract][Full Text] [Related]
8. Different tau epitopes define Abeta42-mediated tau insolubility.
Pennanen L; Götz J
Biochem Biophys Res Commun; 2005 Dec; 337(4):1097-101. PubMed ID: 16226718
[TBL] [Abstract][Full Text] [Related]
9. Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex.
Smith MJ; Sharples RA; Evin G; McLean CA; Dean B; Pavey G; Fantino E; Cotton RG; Imaizumi K; Masters CL; Cappai R; Culvenor JG
Brain Res Mol Brain Res; 2004 Aug; 127(1-2):128-35. PubMed ID: 15306129
[TBL] [Abstract][Full Text] [Related]
10. Neighbored phosphorylation sites as PHF-tau specific markers in Alzheimer's disease.
Singer D; Lehmann J; Hanisch K; Härtig W; Hoffmann R
Biochem Biophys Res Commun; 2006 Aug; 346(3):819-28. PubMed ID: 16781671
[TBL] [Abstract][Full Text] [Related]
11. Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains.
Zhou XW; Li X; Bjorkdahl C; Sjogren MJ; Alafuzoff I; Soininen H; Grundke-Iqbal I; Iqbal K; Winblad B; Pei JJ
Neurobiol Dis; 2006 Jun; 22(3):657-68. PubMed ID: 16513361
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphorylation of tau induces local polyproline II helix.
Bielska AA; Zondlo NJ
Biochemistry; 2006 May; 45(17):5527-37. PubMed ID: 16634634
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells.
Ojala JO; Sutinen EM; Salminen A; Pirttilä T
J Neuroimmunol; 2008 Dec; 205(1-2):86-93. PubMed ID: 18947885
[TBL] [Abstract][Full Text] [Related]
14. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
15. Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry.
Hoerndli FJ; Pelech S; Papassotiropoulos A; Götz J
Eur J Neurosci; 2007 Jul; 26(1):60-72. PubMed ID: 17587323
[TBL] [Abstract][Full Text] [Related]
16. Granular tau oligomers as intermediates of tau filaments.
Maeda S; Sahara N; Saito Y; Murayama M; Yoshiike Y; Kim H; Miyasaka T; Murayama S; Ikai A; Takashima A
Biochemistry; 2007 Mar; 46(12):3856-61. PubMed ID: 17338548
[TBL] [Abstract][Full Text] [Related]
17. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
18. Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules.
Fischer D; Mukrasch MD; Biernat J; Bibow S; Blackledge M; Griesinger C; Mandelkow E; Zweckstetter M
Biochemistry; 2009 Oct; 48(42):10047-55. PubMed ID: 19769346
[TBL] [Abstract][Full Text] [Related]
19. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
[TBL] [Abstract][Full Text] [Related]
20. Identification of regulatory cis-acting elements for alternative splicing of presenilin 2 exon 5 under hypoxic stress conditions.
Higashide S; Morikawa K; Okumura M; Kondo S; Ogata M; Murakami T; Yamashita A; Kanemoto S; Manabe T; Imaizumi K
J Neurochem; 2004 Dec; 91(5):1191-8. PubMed ID: 15569262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
